United Therapeutics Stock Market Value
| UTHR Stock | USD 367.36 3.03 0.83% |
| Symbol | United |
United Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.188 | Earnings Share 22.77 | Revenue Per Share 60.245 | Quarterly Revenue Growth 0.229 | Return On Assets 0.1189 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
United Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to United Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of United Therapeutics.
| 10/23/2024 |
| 11/22/2024 |
If you would invest 0.00 in United Therapeutics on October 23, 2024 and sell it all today you would earn a total of 0.00 from holding United Therapeutics or generate 0.0% return on investment in United Therapeutics over 30 days. United Therapeutics is related to or competes with Incyte, Alnylam Pharmaceuticals, Ultragenyx, Apellis Pharmaceuticals, Replimune, Nuvalent, and Ventyx Biosciences. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products t... More
United Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure United Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess United Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.02 | |||
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 9.81 | |||
| Value At Risk | (3.07) | |||
| Potential Upside | 2.89 |
United Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for United Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as United Therapeutics' standard deviation. In reality, there are many statistical measures that can use United Therapeutics historical prices to predict the future United Therapeutics' volatility.| Risk Adjusted Performance | 0.0417 | |||
| Jensen Alpha | (0.03) | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0673 |
United Therapeutics Backtested Returns
Currently, United Therapeutics is very steady. United Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0611, which indicates the firm had a 0.0611% return per unit of risk over the last 3 months. We have found thirty technical indicators for United Therapeutics, which you can use to evaluate the volatility of the company. Please validate United Therapeutics' Semi Deviation of 1.89, risk adjusted performance of 0.0417, and Coefficient Of Variation of 2111.77 to confirm if the risk estimate we provide is consistent with the expected return of 0.11%. United Therapeutics has a performance score of 4 on a scale of 0 to 100. The entity has a beta of 1.05, which indicates a somewhat significant risk relative to the market. United Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, United Therapeutics is expected to follow. United Therapeutics right now has a risk of 1.73%. Please validate United Therapeutics maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if United Therapeutics will be following its existing price patterns.
Auto-correlation | -0.84 |
Excellent reverse predictability
United Therapeutics has excellent reverse predictability. Overlapping area represents the amount of predictability between United Therapeutics time series from 23rd of October 2024 to 7th of November 2024 and 7th of November 2024 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of United Therapeutics price movement. The serial correlation of -0.84 indicates that around 84.0% of current United Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.84 | |
| Spearman Rank Test | -0.77 | |
| Residual Average | 0.0 | |
| Price Variance | 360.57 |
United Therapeutics lagged returns against current returns
Autocorrelation, which is United Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting United Therapeutics' stock expected returns. We can calculate the autocorrelation of United Therapeutics returns to help us make a trade decision. For example, suppose you find that United Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
United Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If United Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if United Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in United Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
United Therapeutics Lagged Returns
When evaluating United Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of United Therapeutics stock have on its future price. United Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, United Therapeutics autocorrelation shows the relationship between United Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in United Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against United Stock
| 0.66 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.65 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.63 | MTEM | Molecular Templates | PairCorr |
| 0.62 | NKTX | Nkarta Inc | PairCorr |
| 0.57 | TPST | Tempest Therapeutics | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.